key: cord-0016199-bjo300eo
authors: Sakowicz, Ms. Allie; Rosati, Ms. Jessica; Caldarelli, Leslie A.; Shah, Malika D.; Mithal, Leena B.; Miller, Emily S.
title: Partner Testing of SARS-CoV-2 Positive Women Presenting for Delivery
date: 2021-03-20
journal: Am J Obstet Gynecol MFM
DOI: 10.1016/j.ajogmf.2021.100361
sha: b1fa08afd9880a1bfbb8e2ff97bf62af1c8db5ae
doc_id: 16199
cord_uid: bjo300eo

nan

Many hospitals across the United States currently perform universal SARS-CoV-2 testing on all women admitted for delivery. This maternal case identification has widespread implications ranging from the presence of support persons during delivery to optimizing care of the neonate after discharge. Household contacts, such as the partners of pregnant women with SARS-CoV-2, are considered at high risk of infection acquisition 1 and understanding the SARS-CoV-2 status of the partners of pregnant women has similarly broad implications for the family unit. However, despite evidence supporting the practice, 2 limited efforts have been made to incorporate testing and counseling of partners of women who test positive for SARS-CoV-2 into obstetric care.

This is a retrospective cohort study of women who delivered at Northwestern Memorial Hospital between April 8, 2020, and February 20, 2021. Standard protocol at our institution during the study period was to perform universal SARS-CoV-2 testing on all pregnant women admitted for delivery. During the period ranging from April 8, 2020 to December 7, 2020, women who tested positive upon admission or within ten days prior to delivery were not permitted to have a support person present during their delivery hospitalization, but were asked to identify a support person to undergo SARS-CoV-2 testing in order to aid in discharge planning for the neonate. From December 8, 2020 to February 20, 2021, women who tested positive were permitted to have a support person present and the support person was given the option to obtain an in-house SARS-CoV-2 test. As most women reported their partner as the identified support person, we will use the terminology of partner herein. Partner testing was accomplished either via testing organized by the partner's primary care provider or via direct order placed by the obstetric clinician. The latter initially was administered at an outpatient drive-thru testing site and then was transitioned to rapid point-of-care testing performed by obstetric nurses once testing capacity evolved.

The prevalence of SARS-CoV-2 positivity among partners who underwent testing was calculated. Indeterminate results for partners was considered as presumptive positive and was grouped with positive test results for analysis. Bivariable analyses were performed to identify whether individual patient sociodemographic characteristics were associated with an increased prevalence of partner positivity. A sensitivity analysis was performed excluding partners with indeterminate results. This study was approved by the Northwestern University Institutional Review Board prior to its initiation.

Of 153 women who tested positive for SARS-CoV-2 within 10 days of delivery, 100 (65%) had a partner tested with results accessible in the electronic health record. Of the 100 partners tested, 33 (33%, 95% CI 24.7% -44.3%) resulted as positive or presumptive positive for SARS-CoV-2. No maternal sociodemographic characteristics were associated with partner test results (Table) . A sensitivity analysis excluding partners with an indeterminate test did not change the findings.

Our findings demonstrated that the rate of infection among partners of pregnant women who test positive for SARS-CoV-2 is higher than 16.3%, which is the reported rate of household contacts in the general population. 3 While social determinants of health have been identified as risk factors for SARS-CoV-2 acquisition in the community, 4 sociodemographic characteristics did not appear to be associated with SARS-CoV-2 positivity among these tested partners. The majority of the families received public insurance, and racial and ethnic minority populations were disproportionately represented in these data. We hypothesize that, while social determinants of health are a risk factor for SARS-CoV-2 acquisition in the community, once the infection is in the household, social determinants of health no longer play a major role in affecting risk for close contacts. While no maternal sociodemographic characteristics were identified as being associated with partner positivity, we recognize that our sample size could lead to a Type 2 error and further research into this topic is warranted.

Relying on symptom-based testing would miss identification of more than half of all SARS-CoV-2 cases from household contacts. 2 Our data corroborate these findings and encourage obstetric care providers to consider offering testing for the partners of women who test positive for SARS-CoV-2 at the time of delivery. Knowledge of a partner's test result can better guide shared decision making during the delivery hospitalization, including whether the partner chooses to stay for the delivery, what personal protective equipment should be worn by the partner during labor and NICU visitation guidelines.

The results of empiric partner SARS-CoV-2 testing can also inform isolation versus quarantine recommendations. As perceived community benefits significantly impact adherence to these public health measures, 5 empiric testing may also provide an opportunity to influence partner behavior and mitigate community spread. Findings from empiric testing can also inform discharge planning for the neonate, including targeted counseling and shared decision making on exposure mitigation to the neonate, as well as strategizing on risk containment for caregiver accompaniment to the first pediatric appointments. While it is ideal that all contacts of patients with COVID-19 are tested, there are still many gaps in access to testing. By facilitating completion of testing and counseling on results during the admission for delivery, we believe that this approach can improve reach and optimize safety for new families.

Recommending testing and treatment to an infected partner is already a widely accepted standard for women with chlamydia or gonorrhea infection through expedited partner therapy. 6 Offering universal partner testing of SARS-CoV-2 positive women should similarly be integrated into obstetric care delivery in order to provide comprehensive, holistic care to optimize the health of the entire family unit. 

Transmission of SARS-COV-2 Infections in Households -Tennessee and Wisconsin

SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. The Lancet Infectious Diseases

Characteristics of Household Transmission of COVID-19

Risk factors for severe acute respiratory syndrome coronavirus 2 infection in pregnant women

How to improve adherence with quarantine: rapid review of the evidence

Expedited Partner Therapy in the Management of Sexually Transmitted Diseases: Review and Guidance